Product pipeline and R&Dmixed · 4 filings
“Our research and development costs decreased during the three months ended March 31, 2026, relative to the comparative period in 2025 primarily due to FDA approval of VIZZ.”10-Q · May 11, 2026 ↗
LENZ Therapeutics, Inc.
LENZ
Market read
LENZ Therapeutics, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 10 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
Company-3.9% todayVolume comparison unavailable
Market group0 of 10 activeRNA Therapeutics · unavailable
Disclosed network0 of 5 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- LENZ's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if LENZ's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 10 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- LENZ's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods2
Price observations320
Usable filing statements98
Verified relationships5
Evidence supporting the case
No qualifying supportive evidence was identified.
Evidence challenging the case
- Diluted shares increased 35.4% in the latest annual period.
Questions before a position
- EV/sales is 77% below the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context
Price as of Sep 11, 2026
4.536m-66.9%12m-88.2%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2024-12-31$0—$-2.34—
2025-12-31$19.1M—$-2.85+35.4%
What management says matters
Persistent and emerging business drivers
Legal and regulatory exposuremixed · 3 filings
“The decrease was primarily driven by a $12.1 million decrease in clinical and nonclinical research expense for our clinical trials, and a $2.4 million decrease in contract regulatory consulting expenses associated with the prior period preparation and filing…”10-K · Mar 24, 2026 ↗
Demand and volumemixed · 1 filings
“We believe that the likely demand for a pharmaceutical option is driven by multiple factors, most notably presbyopes seeking to have a functional visual benefit in their day-to-day life, as well as those that want the cosmetic benefit of not requiring reading…”10-K · Mar 24, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 6.8× · EV/sales 5.5×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Fewer than 4 annual revenue periods; too little history to scaffold scenarios.
Price action
How the market is pricing the story
4.53-3.9% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for LENZ. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for LENZ. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind LENZ
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
ABBVAbbVie Inc.competitorMay 11, 2026 ▾
“As VIZZ is marketed for the treatment of presbyopia, we may face competition from a variety of companies developing or marketing other pharmaceutical presbyopia therapies, including AbbVie (formerly Allergan), AceVision, Amneal Therapeutics, Bausch & Lomb, Ey…”
AMRXAmneal Pharmaceuticals, Inc.competitorMay 11, 2026 ▾
“As VIZZ is marketed for the treatment of presbyopia, we may face competition from a variety of companies developing or marketing other pharmaceutical presbyopia therapies, including AbbVie (formerly Allergan), AceVision, Amneal Therapeutics, Bausch & Lomb, Ey…”
GKOSGlaukos CorporationcompetitorMay 11, 2026 ▾
“As VIZZ is marketed for the treatment of presbyopia, we may face competition from a variety of companies developing or marketing other pharmaceutical presbyopia therapies, including AbbVie (formerly Allergan), AceVision, Amneal Therapeutics, Bausch & Lomb, Ey…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
LENZ is currently a Follower in the organic co-movement group RNA Therapeutics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for LENZ; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.